Physician profile
Jayne H Ward
NPI 1700999166
$168,770.29
in general payments reported to CMS, 2019-2025
13 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $49K · 2021: $17K · 2022: $14K · 2023: $3,394 · 2024: $468 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,618 · Food and Beverage: $860 · Consulting Fee: $600 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,618.00 |
| Food and Beverage | $859.71 |
| Consulting Fee | $600.00 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $56,991.18 | 2019-2025 | |
| Emd Serono, INC. | $35,997.31 | 2019-2025 | |
| Celgene Corporation | $25,269.75 | 2019-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $18,050.02 | 2021-2023 | Zeposia |
| Biogen, INC. | $17,064.71 | 2019-2025 | Tysabri, Skyclarys |
| Genentech USA, INC. | $14,765.54 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Novartis Pharmaceuticals Corporation | $492.94 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $30.15 | 2024 | Acthar |
| Alexion Pharmaceuticals, INC. | $23.00 | 2023 | Soliris |
| Abbvie INC. | $22.45 | 2022 | |
| Ucb, INC. | $22.34 | 2023 | Nayzilam |
| Tg Therapeutics, INC. | $21.96 | 2024 | |
| Boston Scientific Corporation | $18.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.